로딩 중…
StockDiggingStockDigging

RP Bio Inc.

314140· KOSDAQ
₩5,200-5.45%
2026-06-19

Price Chart

RP Bio Inc.-9.57%

Financials

Investment Metrics(as of 2026-06-19)

MetricValue
Size
Market Cap45.07B KRW
Revenue137.35B KRW
Net Income5.60B KRW
Total Assets164.69B KRW
Net Assets109.32B KRW
Employees493
Value
P/E8.04x
P/B0.41x
PEG0.15x
P/S0.33x
EV/EBITDA8.38x
FCF Yield12.87%
Profitability
ROE5.12%
ROA3.40%
Op. Margin4.15%
Revenue Growth3.34%
Earnings Growth54.27%
Financial Health
Debt Ratio150.64%
Total Debt16.00B KRW
FCF5.80B KRW
Cash13.25B KRW
Current Ratio1.34x
Net Debt/EBITDA0.48x
Dividend
Div. Yield0.91%
Performance
1Y Return-9.57%
1M Return-11.86%
From 52W High-43.04%
1Y MDD-36.83%
Trading
Volume12,089 shares
Foreign Own.1.98%
Per Share
EPS646 KRW
BPS12,639 KRW

Company Info

CEO 윤재훈
Employees 493
Founded 2016
HQ 서울특별시 강남구, KR
Website rpskorea.com

RP Bio, established in 2016 through a spin-off and listed on KOSDAQ in 2022, is the sole domestic company inheriting Dr. RP Scherer's soft capsule manufacturing technology since 1983. The company manufactures and supplies various pharmaceuticals and health functional foods, including soft capsules, holding over 60% of the domestic soft capsule market share. RP Bio maintains long-term collaborations with major pharmaceutical companies, possesses 28 patents, and pursues global market expansion strategies based on its quality competitiveness.